Phase 3 N=243 Adapalene-Benzoy Peroxide (BPO) Gel in the Treatment of Acne Vulgaris as a 6-month Maintenance
Acne
Primary: Maintenance Success for Total Lesions at Week 24 — 78.9; 45.8 percent of subjects
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=189 Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study
Chronic Nonmalignant Pain
Primary: Number of Participants With Adverse Events (AEs) as a Measure of Safety. — 1; 16; 143 participants
Phase 3 N=88 Erythropoietin (EPO) and Ischemia-reperfusion After Kidney Transplantation
Kidney Transplantation
Primary: Kidney Graft Function by Estimated Glomerular Filtration Rate (eGFR) — 47; 46 ml/min — p=<0.05
Phase 3 N=350 A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma
Asthma
Primary: Possible Drug-Related Adverse Events — 13; 16; 9; 4 participants
Phase 3 N=405 Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery
Ocular Inflammation
Primary: Participants With Complete Resolution of Anterior Chamber Cells and Flare. Grade=0 — 64; 23 participants
Phase 3 N=400 Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery
Ocular Inflammation
Primary: Subjects With Complete Resolution of Anterior Chamber Cells and Flare. Grade=0. — 48; 27; 153; 172 participants
Phase 3 N=204 Safety and Efficacy of Dose Conversion From Vicodin® to Buprenorphine Transdermal System (Butrans™) in Subjects With OA Pain
Osteoarthritis
Primary: The Percentage of Subjects Who Completed the 14-day Double-blind Phase. — 88; 83; 85; 85 Percentage of Participants
Phase 3 N=590 A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)
Human Immunodeficiency Virus - Type 1
Primary: Virological Response at Week 48 (Number of Participants With Plasma Viral Load Less Than 50 Copies/mL) - as Defined by the Time to Loss of Virologic Response (TLOVR)…
Phase 3 N=105 Study of the Efficacy and Safety of Intravenous vs Oral Acetaminophen for Treatment of Fever in Healthy Adult Males
Fever
Primary: The Rapidity of Onset of Antipyretic Effect at 2 Hours (Measured as Weighted Sum of Temperature Differences Over 2 Hours, WSTD2) — 0.3; 0.6 Degrees Celsius
Phase 3 N=60 Safety of Intravenous Acetaminophen Vs Placebo for the Treatment of Endotoxin-Induced Fever in Healthy Adult Males
Fever
Primary: Weighted Sum of Temperature Differences Over 6 Hours (WSTD6) Assessment of the Antipyretic Effect Over 6 h of a Single Dose of IV APAP vs. Placebo for Treatment of…
Phase 3 N=290 Safety of BTDS in Subjects With Osteoarthritic (OA) Pain of Hip or Knee: A 6-Month Open-label Extension Phase
Osteoarthritis
Primary: The Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 0; 6; 202 participants
Phase 3 N=567 Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee
Chronic Pain · Osteoarthritis of the Knee
Primary: "Average Pain Over the Last 24 Hours" Score of the Study Knee at Week 12 of the Double Blind Phase. — 7.16; 7.06; 2.63; 2.74 units on a scale — p=0.0853
Phase 3 N=829 Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis
Ulcerative Colitis
Primary: Endoscopic Remission of Ulcerative Colitis (UC) at 6 Months — 83.7; 81.5 percent of participants
Phase 3 N=40 An Extension to Study AZA PH GL 2003 CL 001 Allowing for Continuation of Azacitidine Treatment in Patients With Myelodysplastic Syndromes (MDS)
Myelodysplastic Syndromes
Primary: Number of Participants in Different Categories of Treatment Emergent Adverse Events for the Extension Period — 39; 27; 20; 5 participants
Phase 3 N=42 Acupuncture for Dry Eye Syndrome
Dry Eye Syndromes
Primary: Ocular Surface Disease Index : OSDI — -17.61; -17.20 Scores on the OSDI score